Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 14, 2026

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
08:29

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

Differential effects of Paclitaxel on dendritic cell function.

Justin John1, Mohammed Ismail, Catherine Riley

  • 1Oncology, Postgraduate Medical School, Daphne Jackson Road, University of Surrey, Guildford GU2 7WG, UK.

BMC Immunology
|March 23, 2010
PubMed
Summary

Chemotherapy agent paclitaxel enhances dendritic cell (DC) function and T-cell proliferation, suggesting it may be beneficial when co-administered with DC cancer vaccines.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HuBMAP Data Portal: A Resource for Multimodal Spatial and Single-Cell Data of Healthy Human Tissues.

ArXiv·2026
Same author

Leflunomide-inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy.

British journal of pharmacology·2026
Same author

The HuBMAP Framework for Advancing Data FAIRness.

bioRxiv : the preprint server for biology·2026
Same author

Correction: Safety and outcomes of laparoscopic bile duct exploration: a UK-wide multi-centre study (R-ALiCE).

Surgical endoscopy·2026
Same author

Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

Science advances·2026
Same author

An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing.

British journal of cancer·2026

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Dendritic cells (DCs) show promise as cancer vaccines.
  • Chemotherapy was previously thought to suppress immune responses, but recent studies indicate otherwise.
  • The interaction between chemotherapy and DC vaccines requires further investigation.

Purpose of the Study:

  • To investigate the effects of paclitaxel on human dendritic cell (DC) biology in vitro.
  • To determine if paclitaxel can be safely co-administered with DC-based cancer vaccines.

Main Methods:

  • In vitro study of human monocyte-derived DCs treated with paclitaxel.
  • Assessment of DC viability, HLA class II expression, T-cell proliferation, endocytic capacity, and cytokine production.
  • Morphological analysis of DCs post-paclitaxel exposure.

Related Experiment Videos

Last Updated: Jun 14, 2026

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
08:29

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

Main Results:

  • DCs exhibited resistance to paclitaxel, maintaining viability at high concentrations.
  • Paclitaxel increased HLA class II expression and allogeneic T-cell proliferation.
  • Paclitaxel reduced DC endocytic capacity and pro-inflammatory cytokine expression (IL-12, TNF-alpha).
  • Morphological changes were observed in immature DCs, but not in LPS-matured DCs.

Conclusions:

  • Paclitaxel has complex effects on human DCs, including immunostimulatory potential.
  • DCs demonstrated resistance to paclitaxel's cytotoxic effects.
  • Co-administration of paclitaxel with DC vaccines may offer clinical advantages due to immunostimulatory effects and DC resistance.